Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
Bianca RaffaelliRoberto De IccoMichele CorradoMaria TerhartJessica AilaniPublished in: Cephalalgia : an international journal of headache (2023)
The open-label study program for calcitonin gene-related peptide-targeted migraine preventives confirms the favorable safety and efficacy profile of these drugs over time. Treatment adherence appears higher than with previous unspecific migraine preventives. Real-world data and post-marketing surveillance studies may corroborate and complement open-label results.
Keyphrases
- open label
- phase ii
- clinical trial
- phase iii
- phase ii study
- study protocol
- cancer therapy
- public health
- quality improvement
- randomized controlled trial
- genome wide
- copy number
- electronic health record
- metabolic syndrome
- drug delivery
- type diabetes
- insulin resistance
- skeletal muscle
- case control
- rectal cancer
- placebo controlled